MCID: CRY008
MIFTS: 39

Cryopyrin-Associated Periodic Syndrome

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Cryopyrin-Associated Periodic Syndrome

MalaCards integrated aliases for Cryopyrin-Associated Periodic Syndrome:

Name: Cryopyrin-Associated Periodic Syndrome 54
Cryopyrin Associated Periodic Syndrome 38 6
Cryopyrin-Associated Periodic Syndromes 74
Cryopyrinopathy 54
Caps 54

Classifications:



External Ids:

KEGG 38 H00282
UMLS 74 C2316212

Summaries for Cryopyrin-Associated Periodic Syndrome

MalaCards based summary : Cryopyrin-Associated Periodic Syndrome, also known as cryopyrin associated periodic syndrome, is related to muckle-wells syndrome and cinca syndrome. An important gene associated with Cryopyrin-Associated Periodic Syndrome is NLRP3 (NLR Family Pyrin Domain Containing 3), and among its related pathways/superpathways are NOD-like receptor signaling pathway and Selenium Micronutrient Network. The drugs Ginseng and Rilonacept have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and heart.

Wikipedia : 77 Cryopyrin-associated periodic syndrome is a group of rare, heterogeneous autoinflammatory disease... more...

Related Diseases for Cryopyrin-Associated Periodic Syndrome

Diseases related to Cryopyrin-Associated Periodic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 muckle-wells syndrome 33.4 CRP IL1R1 NLRP3
2 cinca syndrome 33.3 IL1R1 IL1RN NLRP3
3 familial cold autoinflammatory syndrome 1 32.8 IL1R1 NLRP3
4 mevalonic aciduria 30.4 IL1RN NLRP3
5 amyloidosis aa 30.3 CRP SAA4
6 wells syndrome 30.2 CRP IL1R1 NLRP3
7 familial mediterranean fever 29.8 CRP IL1RN NLRP3 SAA4
8 exanthem 29.6 CRP IL1RN IL6 NLRP3
9 adult-onset still's disease 29.4 CRP IL1R1 IL1RN IL6
10 juvenile rheumatoid arthritis 29.4 CRP IL1R1 IL1RN IL6
11 catastrophic antiphospholipid syndrome 11.5
12 amyloidosis 10.3
13 chronic meningitis 10.3 CRP NLRP3
14 urticaria 10.2
15 cholangitis 10.2 CRP IL6
16 castleman disease 10.2 CRP IL6
17 cold agglutinin disease 10.2 CRP IL6
18 hyper-igd syndrome 10.2 CRP IL1RN
19 uremic pruritus 10.2 CRP IL6
20 neutrophilia, hereditary 10.2 CRP IL6
21 cartilage disease 10.2 CRP IL1RN
22 typhoid fever 10.2 CRP IL6
23 spinal disease 10.2 CRP IL6
24 viral pneumonia 10.2 CRP IL6
25 multicentric castleman disease 10.2 CRP IL6
26 relapsing polychondritis 10.2 CRP IL6
27 central nervous system vasculitis 10.2 CRP IL6
28 subacute thyroiditis 10.2 CRP IL6
29 intussusception 10.2 CRP IL6
30 louse-borne relapsing fever 10.2 CRP IL6
31 cecal disease 10.2 CRP IL6
32 pyelitis 10.2 CRP IL6
33 pericardium disease 10.2 CRP IL1RN
34 ischemic heart disease 10.2 CRP IL6
35 mesenteric lymphadenitis 10.2 CRP IL6
36 viral meningitis 10.2 CRP IL6
37 mycoplasma pneumoniae pneumonia 10.2 CRP IL6
38 hypersensitivity reaction type iii disease 10.2 CRP IL6
39 intermittent explosive disorder 10.2 CRP IL6
40 orbital cellulitis 10.2 CRP IL1RN
41 intermediate coronary syndrome 10.2 CRP IL6
42 systolic heart failure 10.2 CRP IL6
43 acute orbital inflammation 10.2 CRP IL1RN
44 prediabetes syndrome 10.2 CRP IL6
45 acute cystitis 10.2 CRP IL6
46 cystitis 10.2 CRP IL6
47 acute pyelonephritis 10.2 CRP IL6
48 cold urticaria 10.2 IL1R1 NLRP3
49 pyelonephritis 10.2 CRP IL6
50 silicosis 10.2 IL1RN NLRP3

Graphical network of the top 20 diseases related to Cryopyrin-Associated Periodic Syndrome:



Diseases related to Cryopyrin-Associated Periodic Syndrome

Symptoms & Phenotypes for Cryopyrin-Associated Periodic Syndrome

Drugs & Therapeutics for Cryopyrin-Associated Periodic Syndrome

Drugs for Cryopyrin-Associated Periodic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
2
Rilonacept Approved, Investigational Phase 3,Phase 2 501081-76-1 104924
3 Cinnamon Approved Phase 2, Phase 3
4
Calcium polycarbophil Approved Phase 2, Phase 3 126040-58-2
5 Antibodies Phase 3,Phase 2
6 Antibodies, Monoclonal Phase 3,Phase 2
7 Immunoglobulins Phase 3,Phase 2
8 Immunologic Factors Phase 3,Phase 2
9 Vaccines Phase 3
10 Anti-Inflammatory Agents Phase 3,Phase 2
11 Psyllium Phase 2, Phase 3
12 Juzentaihoto Phase 2, Phase 3
13 Mitogens Phase 2, Phase 3
14
Histamine Approved, Investigational Phase 2 51-45-6 774
15
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
16
Tranilast Investigational Phase 2 53902-12-8 93543
17 Antirheumatic Agents Phase 2,Phase 1
18 Interleukin 1 Receptor Antagonist Protein Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 2
20 Histamine Antagonists Phase 2
21 Analgesics Phase 2
22 Calcium, Dietary Phase 2
23 Anti-Allergic Agents Phase 2
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2
25 Histamine H1 Antagonists Phase 2
26
Histamine Phosphate Phase 2 51-74-1 65513
27 Hormones Phase 2
28 Neurotransmitter Agents Phase 2
29 calcium channel blockers Phase 2
30 Platelet Aggregation Inhibitors Phase 2
31 Analgesics, Non-Narcotic Phase 2

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
2 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
3 The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Completed NCT01105507 Phase 3 canakinumab (company code: ACZ885D)
4 Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT01302860 Phase 3 ACZ885
5 Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Completed NCT00991146 Phase 3 canakinumab
6 Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT00685373 Phase 3 Canakinumab (ACZ885)
7 Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT01576367 Phase 3
8 Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo;rilonacept 160 mg
9 Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome Completed NCT00465985 Phase 3 ACZ885;Placebo
10 RHAPSODY Phase 3 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis Recruiting NCT03737110 Phase 3 Rilonacept;Placebo
11 Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet (UCHA) Recruiting NCT03790033 Phase 2, Phase 3 Ucha-Shinki-Hwan;Placebo
12 Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT) Recruiting NCT03374345 Phase 2, Phase 3 Sipjeondaebo-tang Granule;Placebo
13 Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet Recruiting NCT03083522 Phase 3 Ojeok-San;Placebo
14 Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease Terminated NCT00770601 Phase 3 Canakinumab
15 Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2 rilonacept
16 Efficacy and Safety of Canakinumab in Schnitzler Syndrome Completed NCT01276522 Phase 2 Canakinumab
17 A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS) Recruiting NCT03923140 Phase 2 Tranilast
18 HL2351 CAPS Phase II Study Terminated NCT02853084 Phase 2 HL2351
19 Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease Terminated NCT00069329 Phase 1, Phase 2 anakinra
20 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
21 The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria Completed NCT00214851 Phase 1 Kineret (anakinra)
22 Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients Completed NCT01213641
23 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors Completed NCT00933296
24 Phenomics in Autoimmune and Inflammatory Diseases Recruiting NCT02466217
25 Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases) Recruiting NCT00059748
26 Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) Recruiting NCT02974595
27 Kineret CAPS Post Authorisation Study Active, not recruiting NCT02326376 anakinra (Kineret)

Search NIH Clinical Center for Cryopyrin-Associated Periodic Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Cryopyrin-Associated Periodic Syndrome

Anatomical Context for Cryopyrin-Associated Periodic Syndrome

MalaCards organs/tissues related to Cryopyrin-Associated Periodic Syndrome:

42
Skin, Eye, Heart, Neutrophil, Myeloid, Monocytes, Kidney

Publications for Cryopyrin-Associated Periodic Syndrome

Articles related to Cryopyrin-Associated Periodic Syndrome:

(show top 50) (show all 78)
# Title Authors Year
1
An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. ( 30385706 )
2019
2
A Rare Case of Cryopyrin-associated Periodic Syndrome in an Elderly Woman with NLRP3 and MEFV Mutations. ( 30568124 )
2019
3
Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review. ( 30772614 )
2019
4
Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome. ( 30967326 )
2019
5
An Adult Patient With a Novel Mutation in NLRP3 Gene Associated With Cryopyrin-Associated Periodic Syndrome Mimicking Adult-Onset Still Disease. ( 29239927 )
2018
6
Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades. ( 29331074 )
2018
7
Keratoendotheliitis Fugax Hereditaria: A Novel Cryopyrin-Associated Periodic Syndrome Caused by a Mutation in the Nucleotide-Binding Domain, Leucine-Rich Repeat Family, Pyrin Domain-Containing 3 (NLRP3) Gene. ( 29366613 )
2018
8
Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. ( 29678136 )
2018
9
Flare of a Cryopyrin-associated Periodic Syndrome Following Vaccination with Neisseria Meningitidis Polysaccharides. ( 29858461 )
2018
10
Erythema nodosum in an adolescent patient with cryopyrin-associated periodic syndrome. ( 29988644 )
2018
11
CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME-ASSOCIATED UVEITIS AND PAPILLITIS. ( 30134363 )
2018
12
Cryopyrin-associated periodic syndrome (CAPS) in a patient with NLRP3 T348M mutation. ( 30184330 )
2018
13
Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. ( 27974104 )
2017
14
Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). ( 28196516 )
2017
15
Early-onset urticaria: a marker of cryopyrin-associated periodic syndrome. ( 28512856 )
2017
16
Live-attenuated vaccines in a cryopyrin-associated periodic syndrome patient receiving canakinumab treatment during infancy. ( 29152264 )
2017
17
Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS). ( 29285715 )
2017
18
Muckle-Wells syndrome: a rare hereditary cryopyrin-associated periodic syndrome. ( 26218404 )
2017
19
Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. ( 27635935 )
2017
20
Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). ( 27707729 )
2017
21
[Genetics of cryopyrin-associated periodic syndrome]. ( 28197772 )
2017
22
Neutrophilic urticarial dermatosis (NUD) indicating Cryopyrin-associated periodic syndrome associated with a novel mutation of the NLRP3 gene. ( 25732894 )
2016
23
Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. ( 26667214 )
2016
24
Chorea in a patient with cryopyrin-associated periodic syndrome. ( 26683645 )
2016
25
NLRP3 A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome: Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms. ( 27134254 )
2016
26
Comment on: real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome: reply. ( 27208220 )
2016
27
Brief Report: Late-Onset Cryopyrin-Associated Periodic Syndrome Due to Myeloid-Restricted Somatic NLRP3 Mosaicism. ( 27273849 )
2016
28
NLRP3 A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome: Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms. ( 27371654 )
2016
29
Cryopyrin-associated periodic syndrome in Australian children and adults: Epidemiological, clinical and treatment characteristics. ( 27650144 )
2016
30
Sudden cardiac arrest secondary to cardiac amyloidosis in a young woman with cryopyrin-associated periodic syndrome. ( 25883259 )
2015
31
Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. ( 25038238 )
2015
32
Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts. ( 25979514 )
2015
33
Brief Report: Cryopyrin-Associated Periodic Syndrome Caused by a Myeloid-Restricted Somatic NLRP3 Mutation. ( 25988971 )
2015
34
Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. ( 26312542 )
2015
35
A case of cryopyrin-associated periodic syndrome with kidney transplant failure. ( 28509262 )
2015
36
Cryopyrin-associated periodic syndrome. ( 22891689 )
2014
37
Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome. ( 24252030 )
2014
38
Anakinra for cryopyrin-associated periodic syndrome. ( 24308832 )
2014
39
Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. ( 24352339 )
2014
40
Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. ( 24501247 )
2014
41
Cryopyrin associated periodic syndrome with neurological involvement in a 50-year-old patient. ( 24517880 )
2014
42
Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). ( 24773462 )
2014
43
Longterm followup of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody. ( 25086140 )
2014
44
Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy. ( 25349319 )
2014
45
Cryopyrin-associated periodic syndrome. ( 25438464 )
2014
46
Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome. ( 23650909 )
2013
47
Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. ( 23085882 )
2013
48
Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). ( 23380020 )
2013
49
The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. ( 23442610 )
2013
50
Atypical presentation of a cryopyrin-associated periodic syndrome, revealing a novel NLRP3 mutation. ( 23811320 )
2013

Variations for Cryopyrin-Associated Periodic Syndrome

ClinVar genetic disease variations for Cryopyrin-Associated Periodic Syndrome:

6 (show top 50) (show all 100)
# Gene Variation Type Significance SNP ID Assembly Location
1 NLRP3 NM_001243133.1(NLRP3): c.1316C> T (p.Ala439Val) single nucleotide variant Pathogenic rs121908146 GRCh37 Chromosome 1, 247588067: 247588067
2 NLRP3 NM_001243133.1(NLRP3): c.1316C> T (p.Ala439Val) single nucleotide variant Pathogenic rs121908146 GRCh38 Chromosome 1, 247424765: 247424765
3 NLRP3 NM_001243133.1(NLRP3): c.592G> A (p.Val198Met) single nucleotide variant Conflicting interpretations of pathogenicity rs121908147 GRCh37 Chromosome 1, 247587343: 247587343
4 NLRP3 NM_001243133.1(NLRP3): c.592G> A (p.Val198Met) single nucleotide variant Conflicting interpretations of pathogenicity rs121908147 GRCh38 Chromosome 1, 247424041: 247424041
5 NLRP3 NM_001243133.1(NLRP3): c.907G> A (p.Asp303Asn) single nucleotide variant Pathogenic rs121908153 GRCh37 Chromosome 1, 247587658: 247587658
6 NLRP3 NM_001243133.1(NLRP3): c.907G> A (p.Asp303Asn) single nucleotide variant Pathogenic rs121908153 GRCh38 Chromosome 1, 247424356: 247424356
7 NLRP3 NM_001243133.1(NLRP3): c.1032G> A (p.Leu344=) single nucleotide variant Benign/Likely benign rs180177471 GRCh37 Chromosome 1, 247587783: 247587783
8 NLRP3 NM_001243133.1(NLRP3): c.1032G> A (p.Leu344=) single nucleotide variant Benign/Likely benign rs180177471 GRCh38 Chromosome 1, 247424481: 247424481
9 NLRP3 NM_001243133.1(NLRP3): c.1043C> T (p.Thr348Met) single nucleotide variant Pathogenic rs151344629 GRCh37 Chromosome 1, 247587794: 247587794
10 NLRP3 NM_001243133.1(NLRP3): c.1043C> T (p.Thr348Met) single nucleotide variant Pathogenic rs151344629 GRCh38 Chromosome 1, 247424492: 247424492
11 NLRP3 NM_001243133.1(NLRP3): c.1231C> T (p.Leu411=) single nucleotide variant Benign/Likely benign rs148478875 GRCh37 Chromosome 1, 247587982: 247587982
12 NLRP3 NM_001243133.1(NLRP3): c.1231C> T (p.Leu411=) single nucleotide variant Benign/Likely benign rs148478875 GRCh38 Chromosome 1, 247424680: 247424680
13 NLRP3 NM_001243133.1(NLRP3): c.1306A> G (p.Thr436Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs180177465 GRCh37 Chromosome 1, 247588057: 247588057
14 NLRP3 NM_001243133.1(NLRP3): c.1306A> G (p.Thr436Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs180177465 GRCh38 Chromosome 1, 247424755: 247424755
15 NLRP3 NM_001243133.1(NLRP3): c.1389C> T (p.His463=) single nucleotide variant Benign/Likely benign rs111400208 GRCh37 Chromosome 1, 247588140: 247588140
16 NLRP3 NM_001243133.1(NLRP3): c.1389C> T (p.His463=) single nucleotide variant Benign/Likely benign rs111400208 GRCh38 Chromosome 1, 247424838: 247424838
17 NLRP3 NM_001243133.1(NLRP3): c.1463G> A (p.Arg488Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs145268073 GRCh37 Chromosome 1, 247588214: 247588214
18 NLRP3 NM_001243133.1(NLRP3): c.1463G> A (p.Arg488Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs145268073 GRCh38 Chromosome 1, 247424912: 247424912
19 NLRP3 NM_001243133.1(NLRP3): c.1600C> T (p.Leu534=) single nucleotide variant Benign/Likely benign rs116054301 GRCh37 Chromosome 1, 247588351: 247588351
20 NLRP3 NM_001243133.1(NLRP3): c.1600C> T (p.Leu534=) single nucleotide variant Benign/Likely benign rs116054301 GRCh38 Chromosome 1, 247425049: 247425049
21 NLRP3 NM_001243133.1(NLRP3): c.674C> T (p.Ala225Val) single nucleotide variant Conflicting interpretations of pathogenicity rs180177493 GRCh37 Chromosome 1, 247587425: 247587425
22 NLRP3 NM_001243133.1(NLRP3): c.674C> T (p.Ala225Val) single nucleotide variant Conflicting interpretations of pathogenicity rs180177493 GRCh38 Chromosome 1, 247424123: 247424123
23 NLRP3 NM_001243133.1(NLRP3): c.930C> T (p.Asp310=) single nucleotide variant Benign/Likely benign rs143840033 GRCh37 Chromosome 1, 247587681: 247587681
24 NLRP3 NM_001243133.1(NLRP3): c.930C> T (p.Asp310=) single nucleotide variant Benign/Likely benign rs143840033 GRCh38 Chromosome 1, 247424379: 247424379
25 NLRP3 NM_001243133.1(NLRP3): c.937A> G (p.Ile313Val) single nucleotide variant Uncertain significance rs180177501 GRCh37 Chromosome 1, 247587688: 247587688
26 NLRP3 NM_001243133.1(NLRP3): c.937A> G (p.Ile313Val) single nucleotide variant Uncertain significance rs180177501 GRCh38 Chromosome 1, 247424386: 247424386
27 NLRP3 NM_004895.4(NLRP3): c.786G> A (p.Arg262=) single nucleotide variant Benign rs4925543 GRCh38 Chromosome 1, 247424229: 247424229
28 NLRP3 NM_004895.4(NLRP3): c.786G> A (p.Arg262=) single nucleotide variant Benign rs4925543 GRCh37 Chromosome 1, 247587531: 247587531
29 NLRP3 NM_004895.4(NLRP3): c.1407C> T (p.Leu469=) single nucleotide variant Benign/Likely benign rs141637807 GRCh37 Chromosome 1, 247588152: 247588152
30 NLRP3 NM_004895.4(NLRP3): c.1407C> T (p.Leu469=) single nucleotide variant Benign/Likely benign rs141637807 GRCh38 Chromosome 1, 247424850: 247424850
31 NLRP3 NM_001243133.1(NLRP3): c.1020C> T (p.Pro340=) single nucleotide variant Benign/Likely benign rs41311573 GRCh38 Chromosome 1, 247424469: 247424469
32 NLRP3 NM_001243133.1(NLRP3): c.1020C> T (p.Pro340=) single nucleotide variant Benign/Likely benign rs41311573 GRCh37 Chromosome 1, 247587771: 247587771
33 NLRP3 NM_004895.4(NLRP3): c.230C> T (p.Ala77Val) single nucleotide variant Uncertain significance rs200288250 GRCh37 Chromosome 1, 247582326: 247582326
34 NLRP3 NM_004895.4(NLRP3): c.230C> T (p.Ala77Val) single nucleotide variant Uncertain significance rs200288250 GRCh38 Chromosome 1, 247419024: 247419024
35 NLRP3 NM_004895.4(NLRP3): c.2182A> G (p.Ser728Gly) single nucleotide variant Conflicting interpretations of pathogenicity rs147946775 GRCh37 Chromosome 1, 247592912: 247592912
36 NLRP3 NM_004895.4(NLRP3): c.2182A> G (p.Ser728Gly) single nucleotide variant Conflicting interpretations of pathogenicity rs147946775 GRCh38 Chromosome 1, 247429610: 247429610
37 NLRP3 NM_004895.4(NLRP3): c.2617G> A (p.Ala873Thr) single nucleotide variant Uncertain significance rs201867582 GRCh38 Chromosome 1, 247436088: 247436088
38 NLRP3 NM_004895.4(NLRP3): c.2617G> A (p.Ala873Thr) single nucleotide variant Uncertain significance rs201867582 GRCh37 Chromosome 1, 247599390: 247599390
39 NLRP3 NM_004895.4(NLRP3): c.2494C> A (p.Leu832Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs114158404 GRCh38 Chromosome 1, 247434269: 247434269
40 NLRP3 NM_004895.4(NLRP3): c.2494C> A (p.Leu832Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs114158404 GRCh37 Chromosome 1, 247597571: 247597571
41 NLRP3 NM_004895.4(NLRP3): c.3043A> G (p.Lys1015Glu) single nucleotide variant Uncertain significance rs771315000 GRCh37 Chromosome 1, 247611738: 247611738
42 NLRP3 NM_004895.4(NLRP3): c.3043A> G (p.Lys1015Glu) single nucleotide variant Uncertain significance rs771315000 GRCh38 Chromosome 1, 247448436: 247448436
43 NLRP3 NM_004895.4(NLRP3): c.214G> A (p.Val72Met) single nucleotide variant Conflicting interpretations of pathogenicity rs117287351 GRCh38 Chromosome 1, 247419008: 247419008
44 NLRP3 NM_004895.4(NLRP3): c.214G> A (p.Val72Met) single nucleotide variant Conflicting interpretations of pathogenicity rs117287351 GRCh37 Chromosome 1, 247582310: 247582310
45 NLRP3 NM_004895.4(NLRP3): c.2157-7T> C single nucleotide variant Benign rs116546330 GRCh37 Chromosome 1, 247592880: 247592880
46 NLRP3 NM_004895.4(NLRP3): c.2157-7T> C single nucleotide variant Benign rs116546330 GRCh38 Chromosome 1, 247429578: 247429578
47 NLRP3 NM_004895.4(NLRP3): c.2113C> A (p.Gln705Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs35829419 GRCh37 Chromosome 1, 247588858: 247588858
48 NLRP3 NM_004895.4(NLRP3): c.2113C> A (p.Gln705Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs35829419 GRCh38 Chromosome 1, 247425556: 247425556
49 NLRP3 NM_004895.4(NLRP3): c.429C> T (p.Tyr143=) single nucleotide variant Benign/Likely benign rs56710146 GRCh38 Chromosome 1, 247423872: 247423872
50 NLRP3 NM_004895.4(NLRP3): c.429C> T (p.Tyr143=) single nucleotide variant Benign/Likely benign rs56710146 GRCh37 Chromosome 1, 247587174: 247587174

Expression for Cryopyrin-Associated Periodic Syndrome

Search GEO for disease gene expression data for Cryopyrin-Associated Periodic Syndrome.

Pathways for Cryopyrin-Associated Periodic Syndrome

Pathways related to Cryopyrin-Associated Periodic Syndrome according to KEGG:

38
# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621

GO Terms for Cryopyrin-Associated Periodic Syndrome

Cellular components related to Cryopyrin-Associated Periodic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 CRP IL1R1 IL1RN IL6 NLRP3 SAA4

Biological processes related to Cryopyrin-Associated Periodic Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.71 IL1R1 IL1RN IL6
2 cytokine-mediated signaling pathway GO:0019221 9.63 IL1R1 IL1RN IL6
3 cellular response to lipopolysaccharide GO:0071222 9.58 IL1RN IL6 NLRP3
4 regulation of inflammatory response GO:0050727 9.52 IL1R1 NLRP3
5 response to glucocorticoid GO:0051384 9.51 IL1RN IL6
6 defense response to Gram-positive bacterium GO:0050830 9.5 CRP IL6 NLRP3
7 positive regulation of interleukin-6 production GO:0032755 9.49 IL1RN IL6
8 interleukin-1-mediated signaling pathway GO:0070498 9.48 IL1R1 IL1RN
9 negative regulation of lipid storage GO:0010888 9.37 CRP IL6
10 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.26 IL6 NLRP3
11 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.16 IL1RN IL6
12 response to interleukin-1 GO:0070555 9.13 IL1R1
13 acute-phase response GO:0006953 9.13 CRP IL6 SAA4
14 inflammatory response GO:0006954 9.02 CRP IL1R1 IL1RN IL6 NLRP3

Sources for Cryopyrin-Associated Periodic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....